LSI

We're looking forward to attending The MedTech Conference, hosted by our partners at AdvaMed. As momentum in our industry continues to build after a strong 1H 2024, #MTC24 will feature a record number of companies participating as exhibitors, company presenters, and speakers. Our Chief Business Officer, Henry Peck, will be onsite, with the first edition of "The Lens" our new magazine in hand. Stop by and meet him to get your free copy. See you in Toronto.

While the days might be getting shorter, the LSI Alumni’s list of accomplishments keeps growing longer. This week the #LSIAlumni secured new funding, received FDA Breakthrough Device Designation, appointed new board members, and much more on the road to LSI USA ‘25. Your 60-second news recap: 4C Medical Technologies, Inc. — Saravana Kumar → Commenced enrollment in the A Transseptal Left Atrial System for Treatment of Mitral Regurgitation (ATLAS) trial in the United States and Europe. AccurKardia — Juan C Jimenez, Mohamed Sadeq Ali → Received FDA Breakthrough Device Designation for its ECG-based, AI-powered aortic valve stenosis screening software. CardiaCare — Amos Ziv → Enrolled the first patient in its NeuroPulse Post-Ablation clinical trial with Mount Sinai Health System. InspireMD — Shane Gleason → Announced IDE application approval from the FDA to initiate its CGUARDIANS II pivotal study. Innitius — Rubén Molina → Announced the latest results from its FB-CT1 clinical study assessing the usability and efficacy of its FineBirth device in predicting preterm labor risk. Lymphatica Medtech — Marco Pisano → Raised a €17.9M Series B funding round co-lead by LSI Alumni investor Panakes Partners, TechWald Next S.p.A, and CDP Venture Capital SGR's Digital Transition Fund. Reprieve Cardiovascular — Mark Pacyna → Completed enrollment in the Fluid Management of Acute Decompensated Health Failure Subjects Treated with Reprieve System (FASTR) trial. SymPhysis Medical — Tim Jones → Secured €2.2M in funding for developing its digital catheter-based device for treating fluid buildup in the body due to late-stage cancers. Vitestro — Toon Overbeeke → Appointed LSI Alumni Dave Hickey to its Board of Directors as an independent board member. Congratulations to all the LSI Alumni who made major milestones this week!

Continuing with our series, today’s letter is N — for Neuromodulation. The neuromodulation market is growing rapidly and continues to attract strong innovation, investment, and M&A activity. According to LSI’s Market Intelligence, the neurostimulation market was valued at nearly $6.6 billion in 2023 and is projected to increase at a compound annual growth rate (CAGR) of 7.7% from 2023 to 2028. During the LSI Europe ‘24 panel, “Neuromodulation: Challenges, Ethics, and Unmet Needs Driving Innovation and Investment,” leading investors and innovators shared their insights on the latest advancements and investment opportunities in the field. They also tackled the complex ethical dilemmas that these emerging technologies present. Featured Panelists: • Ana Maiques (Moderator), CEO, Neuroelectrics • Bálint Várkuti, Co-Founder & CEO, CereGate • Catherine Poulin-Filion, Principal, Venture Capital, Sectoral Asset Management • Melissa Lezameta, Associate, Epidarex Capital • Meron Gribetz, Founder & CEO, Inner Cosmos Stay tuned for the full video recording which will become available in the coming weeks. PS: Registration is now open for LSI Europe ‘25 next September 7th - 11th in London. Secure your spot today to take advantage of our best rates and secure your hotel room onsite.

The ABCs of LSI Europe ‘24 — Today’s letter of the day is “N”. Here are the emerging Medtech and Healthtech companies who presented on stage that start with the letter N: • Nano4Imaging — Rudolf Schulze Vohren • Nanobioplus — Guilherme Andrade Santana • NEMESIS Co. Ltd. — Sung Ho Wang • Neshima Medical — Yan Ostrovski, PhD • Neuro Event Labs Oy — Kaapo Annala • Neuroelectrics — Ana Maiques • NEVENT — Rhodel Dacanay • NIMBLE Diagnostics — Oriol Iborra Egea • Nitinotes Surgical — Lloyd Diamond • Nostics — Jeroen Nieuwenhuis • NovaResp - Respiratory AI — Hamed Hanafi • Novuson Surgical Inc. — Stuart Mitchell • Noze — Karim Aly Tune in each day as we recap LSI Europe ‘24 from A to Z. PS: Our 2025 event schedule is now set with three events across the globe: • LSI USA '25: March 17th – 21st (Dana Point, CA) • LSI Asia '25: June 10th – 13th (Singapore) • LSI Europe '25: September 7th – 11th (London) Visit our website or connect with our team to secure your spot at the best rate for any of our 2025 events.

Is today’s financing model aligned with the rapid acceleration of technology, the evolving investment landscape, and the dynamics of the acquisition and exit environment? In this clip, Adam Rosenwach, Chief Business Officer at Deerfield Catalyst, discusses how the traditional financing model needs a shift towards more entrepreneurial thinking. He emphasizes the need for both investors and entrepreneurs to align incentives and adopt new approaches, like the build-to-buy model. As Adam puts it, "There’s a complete mismatch of incentives when VCs want to put as much money into a company as possible, while strategics don’t want to spend as much on an acquisition. Why aren’t we working together to bring in the right amount of capital for a set acquisition price to drive progress and give young entrepreneurs the chance to build a track record?" To dive deeper into this discussion, watch the full LSI Europe ‘24 panel, "Training and Supporting the Next Wave of Entrepreneurs Through Mentorship and Capital." The panel features insights from leading experts on mentorship, venture capital, and strategies to foster innovation and entrepreneurship in Medtech. Featured Panelists: • Joe Mullings (Moderator), Chairman & CEO, The Mullings Group • Ashley Seehusen, Venture Partner, SANTÉ Ventures & CEO at Sante Accel • Adam Rosenwach, Chief Business Officer, Deerfield Catalyst • Dr. Gal Noyman - Veksler, Partner, LionBird • Shai Policker, CEO, MEDX Xelerator LP Catch the full panel on our website and YouTube channel, and stay tuned for more panels coming your way. Want to attend our next event? LSI USA ‘25 will be held March 17th-21st in Dana Point, California. Apply today on our website.

Continuing with our series, today’s letter is M — for Mayo Clinic. For the first time at LSI Europe ‘24, we introduced Workshops to complement the roundtable panel discussions throughout the event. These workshops were designed to focus on single-theme educational content, facilitating live audience engagement, Q&A, and more. One of the many highlights was a session led by Nir G., Technology Development Manager, and Shai Ran Sapir, Associate Technology Development Manager II at Mayo Clinic Ventures. Their workshop, “How Can Innovative Companies Partner With the Mayo Clinic?” offered attendees a deep dive into the opportunities and pathways for collaboration with one of the world’s leading medical institutions. Thank you, Nir and Shai, for hosting this insightful session, and to everyone who participated!

Lymphatica Medtech (#LSIAlumni) raised a €17.9M Series B funding round co-led by Panakes Partners, TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund. A new relationship that led to this deal was built last year at LSI Europe ‘23: “Lymphatica has developed the first clinical solution for a huge unmet need - lymphedema, affecting tens of millions of patients in the US and EU alone. I met Lymphatica at LSI Europe '23 in Barcelona. LSI helped me discover the opportunity and exchange ideas with potential co-investors about the disease and solution.” - Alessio Beverina, Co-Founder & General Partner at Panakes Partners The round also included participation from OCCIDENT, Zürcher Kantonalbank, Club Degli Investitori, and existing investor High-Tech Gründerfonds (HTGF). The company intends to use the funds to accelerate the clinical development and validation of LymphoDrain, an implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions worldwide. Congratulations to Marco Pisano, Co-Founder and CEO, and the entire Lymphatica Medtech team on this tremendous milestone in their commitment to significantly improving the well-being of patients suffering from lymphatic diseases.

AccurKardia (#LSIAlumni) has received FDA Breakthrough Device Designation for AI-powered, ECG-based aortic valve stenosis screening software. This achievement represents a significant step forward in AccurKardia’s mission to broaden the role of ECGs as a comprehensive biomarker, aiming for earlier detection and more effective management of aortic stenosis. Traditionally, aortic valve stenosis is diagnosed through physical exams, auscultation, and echocardiography, but challenges like limited symptom recognition, lack of heart murmurs, and restricted access to diagnostic tools can lead to missed cases. AccurKardia’s software leverages existing ECG data from a center’s EHR system to identify patients at risk for aortic valve stenosis, seamlessly integrating AI-powered screening into current workflows to enhance the chances of timely intervention and transform how we identify and treat this condition, making advanced care more accessible and proactive. Congratulations to LSI Alumni Juan C Jimenez, Mohamed Sadeq Ali, Moin Hussaini, and the entire AccurKardia team on this major milestone. To catch the latest from AccurKardia, tune into Juan Jimenez and Moin Hussaini’s Studio Interview and presentation from LSI USA ‘24 to learn more about AccurKardia’s recent progress. Available on our website and YouTube channel.

The ABCs of LSI Europe ‘24 — Today’s letter of the day is “M”. Here are the emerging Medtech and Healthtech companies who presented on stage that start with the letter M: • machineMD — Dominic Senn • Maculaser Ltd — Jani Tirronen • MDsim — Roger Assaker • Medyria — Mauro Sette • Methinks AI — Pau Rodríguez • Metyos — Alexandre Boulanger • Mirai Medical — Declan Soden • Modra Pharmaceuticals — Eric van der Putten • Myka Labs, Inc. — Dan Laser Tune in each day as we recap LSI Europe ‘24 from A to Z. PS: Our 2025 event schedule is now set with three events across the globe: • LSI USA '25: March 17th – 21st (Dana Point, CA) • LSI Asia '25: June 10th – 13th (Singapore) • LSI Europe '25: September 7th – 11th (London) Visit our website or connect with our team to secure your spot at the best rate for any of our 2025 events.

Syndicates of cross-border investors can serve as a powerful catalyst for Medtech startups aiming to scale globally. By uniting diverse funding, strategic insights, and access to international markets, these partnerships can accelerate growth beyond borders. But it’s not just about the capital. As Robert J. Krummen, CEO of Vektor Medical, Inc., points out, the real value lies in the expertise and market experience that investors bring to the table. In this clip, Rob shares how his investors' knowledge and connections in Europe unlocked new opportunities that went far beyond just funding. At LSI Europe ‘24, the panel "Building Syndicates of Cross-Border Investors in Medtech Companies" explored the experiences of both investors and innovators navigating these strategic partnerships. Featured Panelists: • Ashley Seehusen (Moderator), Venture Partner SANTÉ Ventures & CEO at Santé Accel • Robert J. Krummen, CEO, Vektor Medical, Inc. • C David Adair MD, MBA, FACOG, FASH, C-EFM, Managing Partner & Co-Founder, Solas BioVentures • Dr. Luc Marengereère, Managing Partner, TVM Capital Life Science • Alexander Goemans, CFO, Xeltis Catch the full panel on our website and YouTube channel, and stay tuned for more panels coming your way. Want to attend our next event? LSI USA ‘25 will be held March 17th-21st in Dana Point, California. Apply today on our website.